全文获取类型
收费全文 | 235237篇 |
免费 | 14829篇 |
国内免费 | 988篇 |
专业分类
耳鼻咽喉 | 2523篇 |
儿科学 | 5989篇 |
妇产科学 | 4417篇 |
基础医学 | 29312篇 |
口腔科学 | 4319篇 |
临床医学 | 24073篇 |
内科学 | 49560篇 |
皮肤病学 | 3235篇 |
神经病学 | 23663篇 |
特种医学 | 10110篇 |
外国民族医学 | 13篇 |
外科学 | 37017篇 |
综合类 | 2540篇 |
现状与发展 | 1篇 |
一般理论 | 177篇 |
预防医学 | 16525篇 |
眼科学 | 5529篇 |
药学 | 15489篇 |
1篇 | |
中国医学 | 319篇 |
肿瘤学 | 16242篇 |
出版年
2023年 | 1339篇 |
2022年 | 2192篇 |
2021年 | 5330篇 |
2020年 | 3047篇 |
2019年 | 5052篇 |
2018年 | 6050篇 |
2017年 | 4445篇 |
2016年 | 4850篇 |
2015年 | 5731篇 |
2014年 | 8350篇 |
2013年 | 11245篇 |
2012年 | 17275篇 |
2011年 | 18011篇 |
2010年 | 10068篇 |
2009年 | 9312篇 |
2008年 | 15861篇 |
2007年 | 16658篇 |
2006年 | 16201篇 |
2005年 | 16054篇 |
2004年 | 15102篇 |
2003年 | 13785篇 |
2002年 | 13184篇 |
2001年 | 1929篇 |
2000年 | 1434篇 |
1999年 | 2003篇 |
1998年 | 2784篇 |
1997年 | 2216篇 |
1996年 | 1922篇 |
1995年 | 1761篇 |
1994年 | 1526篇 |
1993年 | 1492篇 |
1992年 | 977篇 |
1991年 | 927篇 |
1990年 | 783篇 |
1989年 | 743篇 |
1988年 | 680篇 |
1987年 | 614篇 |
1986年 | 639篇 |
1985年 | 682篇 |
1984年 | 911篇 |
1983年 | 786篇 |
1982年 | 1035篇 |
1981年 | 964篇 |
1980年 | 837篇 |
1979年 | 464篇 |
1978年 | 515篇 |
1977年 | 447篇 |
1976年 | 419篇 |
1975年 | 316篇 |
1974年 | 310篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
Barry L Eppley A Michael Sadove David Hennon John A van Aalst 《The Cleft palate-craniofacial journal》2006,43(3):374-378
OBJECTIVE: A series of nasopharyngeal appliance designs is presented that represents our evolving experience over a 20-year period in the adjunctive use of prosthetic stents in the surgical correction of nasopharyngeal stenosis. DESIGN: Retrospective assessment of effectiveness of two nasopharyngeal stenosis hollow stent designs in a consecutive series of patients for relief of nasal obstructive symptoms. SETTING: Tertiary academic medical center, Craniofacial Program at Children's Hospital. PATIENTS: Four patients with nasopharyngeal stenosis were treated with a preoperatively fabricated stent made from a clasped palatal appliance onto which hollow acrylic conduits were extended through surgically re-created pharyngeal ports. A subsequent set of four patients with nasopharyngeal stenosis were treated with intraoperatively-fashioned silastic grommets, as opposed to palatal appliances. INTERVENTIONS: Postoperative intraoral stenting of nasopharyngeal ports. MAIN OUTCOME MEASURES: Maintenance of pharyngeal port opening after 1 year, improvement in nasal airway obstructive symptoms. RESULTS: The palatal appliance stents were less well tolerated and had a lower maintenance of port patency after device removal (4 of 8, 50%). The silastic grommets provided better retention into the ports and increased patient tolerance, as well as better 1-year port maintenance (6 of 8, 75%). CONCLUSIONS: The grommet stent appliance offers numerous advantages over a conventional dental-clasped appliance for prosthetic nasopharyngeal stenting, including obviation of extensive preoperative preparation, ease of insertion and removal, and exchange of air during the stenting period. Improved nasopharyngeal patency with this device may be due to greater patient tolerance and subsequent longer use. 相似文献
53.
54.
55.
Hideki Kawaguchi Kazuko Masuo Tomohiro Katsuya Ken Sugimoto Hiromi Rakugi Toshio Ogihara Michael L Tuck 《Hypertension research》2006,29(12):951-959
High blood pressure (BP) is a major determinant of cardiovascular events in obesity. The beta2- and beta3-adrenoceptor polymorphisms are associated with obesity and hypertension. In the present study, we examine the relationships of beta2- and beta3-adrenoceptor polymorphisms with further weight gain-induced BP elevation in obese subjects. Changes in BP, body weight, total body fat-mass, waist-to-hip ratio, plasma norepinephrine (NE) and leptin levels, and beta2(Arg16Gly)- and beta3(Trp64Arg)-adrenoceptor polymorphisms were measured periodically over a 5-year period in 55 entry obese (body mass index [BMI]> or =25.0 kg/m(2)) normotensive (BP<140/90 mmHg) men. BP elevation and weight gain were defined as > or =10% increases from entry levels over 5 years in mean BP or BMI. Obese subjects with weight gain, BP elevation or weight gain-induced BP elevation had higher frequencies of the Gly16 allele of Arg16GIy and Arg64 allele of Trp64Arg. Subjects carrying the Gly16 or Arg64 alleles had significantly greater total fat-mass and waist-to-hip ratio at entry and over a 5-year period compared to the subjects who did not carry these polymorphisms. Subjects carrying the Gly16 allele had similar levels of plasma NE, higher levels of plasma leptin and a lower slope of the regression lines between plasma leptin and NE levels. Those carrying the Arg64 allele had higher plasma NE levels at entry and over a 5-year period compared to the subjects without the Arg64 allele, but plasma leptin levels and slopes were similar. The findings demonstrate that the Arg64 allele of the beta3-adrenoceptor polymorphisms relates to weight gain-induced BP elevation accompanying high plasma NE (heightened sympathetic activity) in obese men. The Gly16 allele of the beta2-adrenoceptor polymorphisms links to weight gain-induced BP elevation associated with leptin resistance. beta2- and beta3-adrenoceptor polymorphisms could predict the future BP elevation and further weight gain-induced BP elevation in originally obese subjects. 相似文献
56.
57.
58.
59.
Christoph Mulert Georg Juckel Michael Brunnmeier Susanne Karch Gregor Leicht Roland Mergl Hans-Jürgen M?ller Ulrich Hegerl Oliver Pogarell 《Clinical EEG and neuroscience》2007,38(2):78-81
During the last 10 years the knowledge about rostral anterior cingulate cortex (ACC) activity in major depression has substantially increased. Several groups have independently described a relationship between resting activity in this area and response to antidepressant treatment. We have recently confirmed a relationship between resting activity of rostral ACC activity and response in a group of 20 patients with major depression using resting theta activity. In this earlier study regions of interest (ROI) were defined in order to establish regional specificity. Differences between responders and nonresponders were only found in the ACC-ROI, but not in the posterior cingulate region. We have now reanalyzed our data using a whole brain voxelwise approach, in order not to miss any other relevant functional differences. In addition to major differences between responders and nonresponders in the rostral ACC, we have identified a nearby region in the midline orbito-frontal region. 相似文献
60.
Hazel B Breitz Richard E Wendt Michael S Stabin Sui Shen William D Erwin Joseph G Rajendran Janet F Eary Lawrence Durack Ebrahim Delpassand William Martin Ruby F Meredith 《Journal of nuclear medicine》2006,47(3):534-542
166Ho-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonate (DOTMP) is a tetraphosphonate molecule radiolabeled with 166Ho that localizes to bone surfaces. This study evaluated pharmacokinetics and radiation-absorbed dose to all organs from this beta-emitting radiopharmaceutical. METHODS: After two 1.1-GBq administrations of 166Ho-DOTMP, data from whole-body counting using a gamma-camera or uptake probe were assessed for reproducibility of whole-body retention in 12 patients with multiple myeloma. The radiation-absorbed dose to normal organs was estimated using MIRD methodology, applying residence times and S values for 166Ho. Marrow dose was estimated from measured activity retained after 18 h. The activity to deliver a therapeutic dose of 25 Gy to the marrow was determined. Methods based on region-of-interest (ROI) and whole-body clearance were evaluated to estimate kidney activity, because the radiotracer is rapidly excreted in the urine. The dose to the surface of the bladder wall was estimated using a dynamic bladder model. RESULTS: In clinical practice, gamma-camera methods were more reliable than uptake probe-based methods for whole-body counting. The intrapatient variability of dose calculations was less than 10% between the 2 tracer studies. Skeletal uptake of 166Ho-DOTMP varied from 19% to 39% (mean, 28%). The activity of 166Ho prescribed for therapy ranged from 38 to 67 GBq (1,030-1,810 mCi). After high-dose therapy, the estimates of absorbed dose to the kidney varied from 1.6 to 4 Gy using the whole-body clearance-based method and from 8.3 to 17.3 Gy using the ROI-based method. Bladder dose ranged from 10 to 20 Gy, bone surface dose ranged from 39 to 57 Gy, and doses to other organs were less than 2 Gy for all patients. Repetitive administration had no impact on tracer biodistribution, pharmacokinetics, or organ dose. CONCLUSION: Pharmacokinetics analysis validated gamma-camera whole-body counting of 166Ho as an appropriate approach to assess clearance and to estimate radiation-absorbed dose to normal organs except the kidneys. Quantitative gamma-camera imaging is difficult and requires scatter subtraction because of the multiple energy emissions of 166Ho. Kidney dose estimates were approximately 5-fold higher when the ROI-based method was used rather than the clearance-based model, and neither appeared reliable. In future clinical trials with 166Ho-DOTMP, we recommend that dose estimation based on the methods described here be used for all organs except the kidneys. Assumptions for the kidney dose require further evaluation. 相似文献